PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Non-small Cell Lung Cancer Clinical Trial

— PROGRESS  

Official title:

PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02804776
• Other study ID #: ECRU-LUNG-2013
• Status: Completed
• Phase: Phase 2
• Start date: January 27, 2015
• Est. completion date: February 21, 2018

Study information

• Verified date: May 2021
• Source: National Cancer Centre, Singapore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.

Description:

Selected patients will receive 4 weeks of gefitinib before surgery. A Positron Emission Tomography - Computed Tomography (PET- CT) will be performed before and after gefitinib to assess the response. Circulating tumour cells (CTCs) and plasma Deoxyribonucleic acid (DNA) will be acquired at baseline, 2 weeks and 4 weeks after gefitinib treatment. Resected tumor will be sectored in details to study the spatial heterogeneity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: February 21, 2018
• Est. primary completion date: February 21, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• EGFR mutation positive Non-Small Cell lung cancer (NSCLC) (regardless of smoking status), or control group may encompass other molecular subtypes of lung cancer e.g. anaplastic lymphoma kinase (ALK) and Kirsten rat sarcoma viral oncogene homolog (KRAS).
• All early stage patients with NSCLC who are deemed surgically resectable.
• All patients must have histologically proven NSCLC, with known EGFR mutation
• Patients should be fit for either lobectomy/ pneumonectomy with or without lymph node sampling.
• Primary tumour should be at least 2 cm in size (Tumor stage 1b).
• Willing to provide informed consent.

Exclusion Criteria:

• Known severe hypersensitivity to gefitinib or any of the excipients of this product
• Any serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
• Interstitial lung disease (ILD) or pulmonary fibrosis; impaired pulmonary function (e.g. FEV1 <40% predicted value, artery blood gas PaO2<60mmHg)
• Patients with prior exposure to agents directed at the Human epidermal receptor (HER) axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
• Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer therapy (e.g. monoclonal antibody therapy) for lung cancer.
• Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within six months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
• Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the subject at high risk for treatment-related complications.
• Patient who has serious active infection.
• Patients who harbouring exon 20 T(Threonine)790M (Methionine) mutation.
• Pregnancy or breast feeding.

Related Conditions & MeSH terms

• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Gefitinib
250mg oral daily for 4 weeks

Locations

Country	Name	City	State
Singapore	National Cancer Centre	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Clonal heterogeneity using whole exome and RNA-sequencing of tumour sectors as well as resected lymph nodes		4 to 6 weeks
Other	Clonal heterogeneity recapitulation through CTC, plasma DNA and functional imaging		4 to 6 weeks
Primary	EGFR TKI sensitivity biomarkers determination	Determine EGFR tyrosine kinase inhibitor (TKI) sensitivity biomarkers in responders vs non responders, as categorized by either Response Evaluation Criteria In Solid Tumors (RECIST) stable disease (SD) vs Partial response (PR) or median percentage tumour shrinkage	4 to 6 weeks
Secondary	Response rates after 4 weeks of neoadjuvant gefitinib	To determine response rates after 4 weeks of neoadjuvant gefitinib as evaluated by RECIST 1.1	4 to 6 weeks